Epidemiology of hepatitis C virus in Iran

In Iran, the prevalence of hepatitis C virus (HCV) infection is relatively low according to the populationb a s e d e p i d e m i o l o g i c a l s t u d i e s . H o w e ve r, t h e epidemiology of HCV is changing and the rate of HCV infection is increasing due to the growth in the number of injecting drug users in the society. In addition, a shift has occurred in the distribution pattern of HCV genotypes among HCV-infected patients in Iran. Genotype 1a is the most prevalent genotype in Iran, but in recent years, an increase in the frequency of 3a and a decrease in 1a and 1b have been reported. These variations in the epidemiology of HCV reflect differences in the routes of transmission, status of public health, lifestyles, and risk factors in different groups and geographic regions of Iran. Health policy makers should consider these differences to establish better strategies for control and prevention of HCV infection. Therefore, this review was conducted to present a clear view regarding the current epidemiology of HCV infection in Iran. Key words: Hepatitis C virus; Blood donors; Injecting drug users; Hemodialysis; Hemophilia; Thalassemia; Genotypes; Occult hepatitis C virus; Epidemiology; Ira

Epidemiology of hepatitis C virus in Iran

In Iran, the prevalence of hepatitis C virus (HCV) infection is relatively low according to the populationb a s e d e p i d e m i o l o g i c a l s t u d i e s . H o w e ve r, t h e epidemiology of HCV is changing and the rate of HCV infection is increasing due to the growth in the number of injecting drug users in the society. In addition, a shift has occurred in the distribution pattern of HCV genotypes among HCV-infected patients in Iran. Genotype 1a is the most prevalent genotype in Iran, but in recent years, an increase in the frequency of 3a and a decrease in 1a and 1b have been reported. These variations in the epidemiology of HCV reflect differences in the routes of transmission, status of public health, lifestyles, and risk factors in different groups and geographic regions of Iran. Health policy makers should consider these differences to establish better strategies for control and prevention of HCV infection. Therefore, this review was conducted to present a clear view regarding the current epidemiology of HCV infection in Iran. Key words: Hepatitis C virus; Blood donors; Injecting drug users; Hemodialysis; Hemophilia; Thalassemia; Genotypes; Occult hepatitis C virus; Epidemiology; Ira

Epidemiology of Hepatitis E in Pregnant Women and Children in Iran: A General Overview

From an epidemiological point of view, hepatitis E is an old infection in Iran, but only recently has its importance as a public health concern been considered from research and public health standpoints. As such, there is still a long road ahead to clarify the real burden of hepatitis E virus (HEV) infection in Iran. According to the available epidemiological studies, the seroprevalence of HEV infection among pregnant women is between 3.6% and 7.4%, and among Iranian children is between 0.9% to 8.5%, varying by geographic regions within the country and directly dependent upon the sanitary status of each. In addition to evaluating the sanitation level of a society, community-based seroprevalence studies of HEV infection demonstrate the most prevalent risk factors, the major routes of transmission, and the epidemiological patterns of HEV among that country’s population. In this review, the current knowledge about the pathogenesis and epidemiology of HEV infection in pregnant women and children in Iran, as well as the recent advances in diagnosis, prevention and treatment of HEV infection have been summarized

Epidemiology of hepatitis E virus in Iran

Iran is known as an endemic country for hepatitis E virus (HEV) infection, while there are variations in the epidemiology of HEV infection throughout the country. The available epidemiological studies in different regions of Iran show HEV seroprevalence of 1.1%-14.2% among general population, 4.5% -14.3% among blood donors, 6.1%-22.8% among injecting drug users, 6.3%-28.3% among hemodialysis patients, 1.6%-11.3% among patients infected with other hepatitis viruses, 27.5% among patients with chronic liver disease, 30.8% among kidney transplant recipient patients, and 10%-16.4% among human immunodeficiency virus-infected patients. These variations reflect differences in the status of public health and hygiene, risk factors, and routes of transmission in different regions and groups. Therefore, it is necessary to review the epidemiology of HEV infection to determine the most prevalent risk factors and routes of transmission, and to evaluate the effectiveness of preventive strategies employed in the public health services of the country. Moreover, the other epidemiological aspects of HEV, including the genotypic pattern, extra hepatic manifestations, and incidence of chronic infection need to be investigated among Iranian population to expand the current knowledge on the epidemiology of HEV and to clarify the real burden of HEV infection. Therefore, this review was performed to provide a general overview regarding the epidemiology of HEV in Iran

Prevalence of Hepatitis E Virus among Adults in South-West of Iran

Background. Knowledge regarding prevalence of HEV in general population can be an indicator of the public health and hygiene. Therefore, this study was conducted to evaluate the prevalence ofHEV among adults in South-West of Iran. Methods. Blood samples were taken from510 participants, 206 (40.4%) males and 304 (59.6%) females fromFebruary to July 2014.Detection of anti-HEVIgG and IgM antibodies was carried out by ELISA test. Results.The overall anti-HEV IgG and IgMprevalence rates were 46.1% and 1.4%, respectively.Anti-HEVIgG and IgMseropositivitywere not statistically associated with gender and race/ethnicity.Meanwhile, there were significant differences between the age groups regarding HEV IgG and IgMseropositivity. HEV IgG seroprevalence increased with age from 14.3% in subjects aged 18–30 years to 71.4%in persons over 71 years old, and considerably individuals aged 61 to 70 years had the highest HEV prevalence (90.9%). Also, 5.7% in the age group 18–30 years and 2.2% in the age group 31–40 years were positive for anti-HEV IgM antibodies and the highest rate was observed in subjects aged 18–30 years. Conclusion. In conclusion, high HEV IgG seroprevalence of 46.1% was observed among adults in South-West of Iran

Design and Production of a Multiepitope Construct Derived From Hepatitis E Virus Capsid Protein

The aim of this study was to design a high density multiepitope protein, which can be a promising multiepitope vaccine candidate against Hepatitis E virus (HEV). Initially, conserved and antigenic helper T-lymphocyte (HTL) epitopes in the HEV capsid protein were predicted by in silico analysis. Subsequently, a multiepitope comprising four HTL epitopes with high-affinity binding to the HLA molecules was designed, and repeated four times as high density multiepitope construct. This construct was synthesized and cloned into pET-30a (þ) vector. Then, it was transformed and expressed in Escherichia coli BL21 cells. The high density multiepitope protein was purified by Ni-NTA agarose and concentrated using Amicon filters. Finally, the immunological properties of this high density multiepitope protein were evaluated in vitro. The results showed that the high density multiepitope construct was successfully expressed and purified. SDSPAGE and Western blot analyses showed the presence of a high density multiepitope protein band of approximately 33 kDa. Approximately 1mg of the purified protein was obtained from each liter of the culture media. Moreover, the purified multiepitope protein was capable of induction of proliferation responses, IFN-g ELISPOT responses and IFN-g and IL-12 cytokines production in a significant level in peripheral blood mononuclear cells (PBMCs) isolated from HEV-recovered individuals compared to the control group. In conclusion, the newly produced multiepitope protein can induce significant T helper type 1 responses in vitro, and can be considered as a novel strategy for the development of HEV vaccines in the future. J. Med. Virol

Evaluation the effect of using thyme and oregano powder in comparison to the antibiotic and probiotic supplementation on growth, some immune responses and intestinal morphology of broiler chicks

To determine the effect of using thyme and oregano powder supplementation on performance, some immune response and intestinal morphology of broiler chicks a total of 200 one-day-old Cobb 500 male broiler chicks were divided into the four treatments consisting of five replicates of 10 chicks each. The treatments were as control groups with no herbal, antibiotic and probiotic supplementations. control groups + virginiamycine antibiotic, control groups + protexin probiotic, control groups + 2 % of each thyme and oregano powder supplementation and Control groups + 4 % of each thyme and oregano powder supplementation. The performance parameters such as feed intake, body weight gain and feed conversion ratio were measured during the study period. To determine immunity parameters on days 28, 0.5 mL of 10 % sheep red blood cells suspension was administrated to two chicks per each replicate through and at day 31, 3 mL blood samples were collected from left wing. On day 42, jejunum tissue samples were separated and fixed in (10 %) neutral buffer formalin and were analyzed by auto-processing apparatus, there after the slide sections were prepared by rotary microtome type (Manubeni, Erma-Tokyo, Japan) and the average of villi measurements was reported as a mean for each bird. The result of this study showed that the dietary inclusion of herbals and probiotic had no significant effects on FI and FCR of broiler chicks but higher body weight gain were seen with they received thyme+oregano supplementation. Inclusion of thyme+oregano and probiotic increased humeral immunity in broiler chicks compared to the control (P ≤ 0.05). Additionally heterophil, lymphocyte and their ratio were not influenced by experimental treatments. The villus length, villus width, and crypt depth were increased were the birds feed by oregano and thyme powders. In conclusion in current study some of beneficial acts toward using thyme and oregano powders on performance, some immune parameters and intestinal morphology on broiler chicks were demonstrated

Computational fluid dynamics based optimisation of emergency response vehicles

Formal optimisation studies of the aerodynamic design of Emergency Response Vehicles, typically encountered within the United Kingdom, were undertaken. The objectives of the study were to optimise the aerodynamics of the Emergency Response Vehicles such as Ambulance and Police cars, in terms of drag force. A combination of wind tunnel tests and the Computational Fluid Dynamics (CFD) simulations were used to analyse the flow field and aerodynamic characteristics of Emergency Response Vehicles. The experimental data were used to validate the computer simulations and the good agreement observed gave confidence in the results obtained. Results from computer simulations on the scale models and full-scale models, were also characteristically similar to those of the validated scale model. Computational Fluid Dynamics (CFD) was combined with an efficient optimisation framework to minimize the drag force of three different types of Emergency Response Vehicles, Ambulance Van Conversion, Police Van Conversion and Police Sedan car Conversion. The benefits of employing an airfoil-based roof design and Bezier curve fitting approach which minimizes the deleterious aerodynamic effects of the required front and rear light-bars, were investigated. Optimal Latin Hypercube (OLH) Design of Experiments, the Multipoint Approximation Method (MAM) and surrogate modelling were used for the optimisation. Optimisation results demonstrated a clear improvement of the aerodynamic design of the Emergency Response Vehicles named above. It was also clearly demonstrated that improving the aerodynamic design of Emergency Response Vehicles roof offers a significant opportunity for reducing the fuel consumption and emissions for Emergency Response Vehicles

Evaluating Post-discharge Thromboembolic Events in Patients With COVID-19

Background: COVID-19 is associated with a high rate of thromboembolic events in hospitalized patients, but it is unclear whether this risk remains high after discharge. This study aimed to evaluate the association of underlying factors with post-discharge thrombolytic events in COVID-19 patients and the association of thrombolytic events with subsequent mortality and ischemic heart disease.Methods: In this study, eligible patients with COVID-19 who were admitted to the respiratory ward of Loghman Hakim Hospital, Tehran, Iran, followed up for about 3 months after discharge to record any thromboembolic events. Patients who reported post-discharge thromboembolic events were confirmed based on their diagnostic tests. The Chi-square test was used to evaluate the association between thromboembolic events and qualitative parameters, and an independent t-test was used to evaluate their association with quantitative parameters. Logistic regression analysis was performed to assess the association between independent variables and the composite outcome.Results: Thromboembolic events were diagnosed in 35 patients (5.04%), including Myocardial Infarction (MI) in 17 patients (2.44%), venous thromboembolism in 10 patients (1.44%), and ischemic stroke in 8 patients (1.15%). None of the 26 patients who received thromboprophylaxis had thromboembolic events. During follow-up, 22 patients (3.17%) died, of whom, 10 patients (43.47%) had thromboembolic events. Thromboembolic events were not associated with sedentary life and oxygen (O2) dependency after discharge (P value of 0.40 and 0.098, respectively). Regression analyses showed that thromboembolic events were significantly associated with ischemic heart disease and mortality (P=0.007 and P<0.001, respectively).Conclusion: Our findings support a high rate of post-hospitalization thromboembolic events in COVID-19 patients; however, it needs more large-scale trials